Jacqui Watson

Chief People Officer

Jacqui Watson joined Inivata as Chief People Officer in July 2019 and brings an extensive background of working internationally as an HR Director, People Developer, and consultant within various organizations at a senior level. She has over 20 years’ experience of leading people and business transformation across different sectors including pharma, IT and hospitality.

Throughout her career Jacqui has focussed on inspiring individuals and teams to reach their full potential and in her current role she is responsible for the alignment of our organisational human resource processes to help drive our business success. She was most recently consulting for various companies, where her primary focus was to identify and develop a sustainable supply of leadership and talent from within these organizations.

Jacqui’s focus since joining Inivata has been to provide continued support for the transformation and growth of our organization and culture to achieve our strategic priority of being a ‘great place to work’.

Clive Morris

Chief Executive

Clive joined the leadership team in May 2016 and became CEO in July 2018. Clive worked for over a decade in various key roles at AstraZeneca, where he oversaw R&D and medical affairs projects and groups on a global scale, was involved in R&D strategy, investor relations, and led the major transformation of AstraZeneca’s UK strategic R&D sites and global HQ.

He has extensive experience across all phases of drug development including seven marketed or close-to-market oncology products. Most recently Clive founded and lead Health Innovation Manchester, to develop an innovation ecosystem involving the decentralisation of £6bn per annum of health and social care services. He is also a non-executive director of Wheatsheaf investments and the InnovateUK Medicines Discovery Catapult.

Clive is accredited as a Pharmaceutical Medicine specialist by the UK Royal College of Physicians, has an Executive MBA and trained as a physician at the University of Manchester.

Clive Morris

Chief Executive Officer

Clive joined the leadership team in May 2016 and became CEO in July 2018. Clive worked for over a decade in various key roles at AstraZeneca, where he oversaw R&D and medical affairs projects and groups on a global scale, was involved in R&D strategy, investor relations, and led the major transformation of AstraZeneca’s UK strategic R&D sites and global HQ.

He has extensive experience across all phases of drug development including seven marketed or close-to-market oncology products. Most recently Clive founded and lead Health Innovation Manchester, to develop an innovation ecosystem involving the decentralisation of £6bn per annum of health and social care services. He is also a non-executive director of Wheatsheaf investments and the InnovateUK Medicines Discovery Catapult.

Clive is accredited as a Pharmaceutical Medicine specialist by the UK Royal College of Physicians, has an Executive MBA and trained as a physician at the University of Manchester.

Thomas Schlumpberger PhD

VP, Business Development

Dr Thomas Schlumpberger joined Inivata in August 2018 as VP, Business Development.

Previously, Thomas held a leadership position at Singulex in 2015 as their Head of Diagnostic Business & Vice President Diagnostics with 15+ years’ experience in the IVD, life science and pharmaceutical industries. In his role as VP of Corporate Development and Alliance Management, he was charged with capturing growth opportunities outside of clinical diagnostics. Additionally, he led all collaborations and agreements necessary to grow and operate the Singulex CLIA laboratory and the Singulex diagnostic business. Notably, he sourced and co-negotiated a $50 million minority investment from Grifols. Thomas also previously held key roles within business development at Annai Systems and AliveCor. Here, he identified growth opportunities, managed deals and supported sales and product development efforts. Before then, he served as the Chief Commercial Officer at Invitae (f/k/a Locus Development), where he had responsibilities for commercialization and product launches.

Earlier in his industry career, Thomas served with Epocal as Senior VP of International Sales and Business Development over 5 years. In this role, he successfully executed multiple deals, specifically a $275M trade sale to Alere. He also built and operated the international business, including distribution deals and product launches which drove additional revenues. Before joining the healthcare industry, Thomas served as a Consultant at McKinsey & Company. He currently sits on the board of DxEconomics and serves as Deal Advisor to CroMedX, both in Toronto, ON.

Stacy Chick

Chief Commercial Officer

Stacy brings over 25 years of US healthcare commercial experience to Inivata. Joining the team as a consultant in early 2018, Stacy quickly leveraged her healthcare sales, marketing, market access and operations experience to build and accelerate the commercialization strategy for InVisionFirst®-Lung. Stacy was appointed Chief Commercial Officer effective September 1, 2018. Prior to joining Inivata, Stacy held sales, marketing, market access and general management executive roles leading teams in global and US life science companies including Bristol-Myers Squibb and Sanofi. Throughout her career Stacy was recognized with President’s Club, Pinnacle and TWIN awards for outstanding business results, mentorship and patient advocacy. Stacy earned her MBA in Finance from Rutgers University and her BBA in Marketing from the University of Georgia. Stacy is an Emeritus Member of the Terry College of Business Alumni Board at the University of Georgia, Board Member of Our Brain Bank, and holds membership in the International Association for the Study of Lung Cancer (IASLC), Women’s Business Leadership, Healthcare Businesswomen’s Association, and the Leukemia & Lymphoma Society. She was appointed as a Peer Ambassador at Emory Winship Cancer Center in 2018.

Nitzan Rosenfeld

Chief Scientific Officer

Nitzan is one of Inivata’s founders and its Chief Scientific Officer. He is a world-leader in circulating tumor DNA research and since 2009 leads a research group at the Cancer Research UK Cambridge Institute, part of the University of Cambridge. His work combines new molecular and genomics approaches to develop new diagnostic tools and applications. Previously he was head of Computational Biology at Rosetta Genomics, where he led development of molecular diagnostic tests for cancer. He originally trained in Physics, and specialized in quantitative molecular biology, obtaining a PhD in Systems Biology from the Weizmann Institute of Science, Israel. Nitzan authored dozens of patents and research articles on methods for molecular diagnostics and cell-free DNA analysis. For his contributions, he was awarded the CRUK Future Leaders in Cancer Research prize, the British Association for Cancer Research Translational Research Award, and the Academy of Medical Sciences Foulkes Medal.

Nitzan Rosenfeld PhD

Chief scientific Officer

Nitzan is one of Inivata’s founders and its Chief Scientific Officer. He is a world-leader in circulating tumor DNA research and since 2009 leads a research group at the Cancer Research UK Cambridge Institute, part of the University of Cambridge. His work combines new molecular and genomics approaches to develop new diagnostic tools and applications. Previously he was head of Computational Biology at Rosetta Genomics, where he led development of molecular diagnostic tests for cancer. He originally trained in Physics, and specialized in quantitative molecular biology, obtaining a PhD in Systems Biology from the Weizmann Institute of Science, Israel. Nitzan authored dozens of patents and research articles on methods for molecular diagnostics and cell-free DNA analysis. For his contributions, he was awarded the CRUK Future Leaders in Cancer Research prize, the British Association for Cancer Research Translational Research Award, and the Academy of Medical Sciences Foulkes Medal.

Tim Shannon

Chief Financial Officer

Tim joined Inivata as CFO in July 2016 and manages finance, administration and legal activities. Prior to joining Inivata he formulated and implemented financial controls and process improvements supporting business growth and expansion most recently at Baxano Surgical and Talecris Biotherapeutics. His background in technology, life sciences, and distribution environments is particularly relevant as Inivata moves forward towards commercialization.

While at Talecris, Tim managed the Initial Public Offering (IPO) at a $3.28 billion valuation and has managed merger and acquisition transactions. Tim also has operational business experience across critical issues including budgeting, investor relations, systems implementation, and risk management. Tim has a Bachelor of Science in Business Administration from Appalachian State University and is a CPA, having spent the first 15 years of his career with PwC.

Ramaswamy Govindan MD

Ramaswamy Govindan, MD, is the Anheuser Busch Chair of Medical Oncology and Professor of Medicine in the Department of Medicine at Washington University School of Medicine (WUSM). Dr. Govindan received his medical degree from the University of Madras in India, and undertook internship and residency training in internal medicine at Michael Reese Hospital and Medical Center in Chicago. He completed his fellowship in hematology-oncology at WUSM and joined the faculty in 1998.

He is interested in studying genomic alterations in lung cancer and translating these findings in the clinic. He has led several national and international clinical trials in lung cancer. He is the Principal Investigator for the NCI sponsored ALCHEMIST Trial to study the impact of targeted therapy in early stage lung cancer. He is the co-chair of the lung cancer working group for The Cancer Genome Atlas (TCGA) project and the Cancer Driver Discovery Project (CDDP) funded by the National Cancer Institute (NCI) He is also the Principal Investigator of the NCI sponsored Paul Calabresi K12 Oncology Training Program and the R25 STRENGTH program at WUSM both funded by the NCI.

Robert Tansley

Non-Executive Director

Robert joined Cambridge Innovation Capital as Investment Director in January 2014. After seven years working in hospital medicine, Robert joined the pharma industry in 1996 working in development and regulatory roles at Sanofi, the MHRA and Roche where he led the clinical team for the regulatory approval of Valcyte^®.

Ten years ago, Robert joined the Cambridge based company Arakis and worked as Medical Director until its £106m sale to Sosei Inc. Since that acquisition, Robert has been involved in a number of start-up companies including founding the malaria-focused company Treague, being founding CEO of the University of Copenhagen spin-out Avilex Pharma and being part of the founding management team of KalVista which is developing the first plasma kallikrein inhibitor for diabetic macular edema in collaboration with its scientific co-founders from Harvard Medical School.

Robert qualified in medicine from University College London, he is a member of the Royal College of Obstetricians & Gynaecologists and the Faculty of Pharmaceutical Medicine and has an MBA from London Business School and an M.Phil in Biostatistics from the University of Cambridge.

Craig Richardson

Non-Executive Director

Craig is a Partner in IP Group’s Life Science investment team. He started his career in the pharmaceutical industry in 1998 and worked in new product development for Glaxo Wellcome, followed by a series of business development roles in UK biotech. He was then part of the founding management team of an in vitro diagnostics company before moving into venture capital investment with Inventages, a life science focused VC fund. He subsequently worked for Fusion IP plc, a specialist investor in university spin-out companies, before joining IP Group in 2014.

Craig has a first-class honours degree in Pharmacy from Cardiff University and a PhD from the School of Pharmacy, University of Nottingham. He also holds an MBA with Distinction from the University of Warwick where he was awarded a Sainsbury Management Fellowship from the Royal Academy of Engineering.

Simon Cartmell

Non-Executive Director

With 35 years pharmaceutical, biotech and medtech experience gained in commercial, product development, strategic leadership and corporate executive roles, Simon is a serial entrepreneur in early stage healthcare businesses.

As CEO of ApaTech Ltd, a QMUL spinout, he developed a world leader in orthobiologics prior to its sale to Baxter for $330m in March 2010. Prior to joining ApaTech in 2004, Simon was a Main Board Director of Celltech Group plc, serving as CEO, Celltech Pharmaceuticals, prior to which he served as COO of Vanguard Medica (later Vernalis plc). The early part of his career was spent at Glaxo/Glaxo Wellcome plc in a series of senior UK and international commercial, development, supply chain and strategic development leadership roles. Simon is an Operating Partner within the IP Group Life-Science team and represents their interests on several diagnostic, medtech and digital health Boards of Directors as a Non-Executive Director or Chairman, including Inivata. In 2016 Simon was awarded the OBE for services to the healthcare business sector.

Peter Wrighton-Smith

Non-Executive Director

Dr Wrighton-Smith is the Chief Executive Officer and Founder of Oxford Immunotec Glob al PLC, a high-growth global diagnostics company focussing on monitoring immune-regulated conditions.

Peter has led Oxford Immunotec from the foundation stages, through product development to regulatory approval in over 50 countries, and subsequent worldwide commercialisation via both a kit and a CLIA lab model. Over that time, Oxford Immunotec has raised five rounds of venture funding prior to an IPO on NASDAQ in 2013. Dr Wrighton-Smith has a Masters in Engineering, Economics and Management, and a Doctorate in Medical Engineering, both from University of Oxford.

Jeanne Bolger

Non-Executive Director

Jeanne joined Johnson & Johnson Innovation – JJDC, Inc as Vice President, Venture Investments, in February 2013.

She is based in London, UK at the Johnson & Johnson Innovation Centre. Jeanne’s responsibilities are focused on investing in and managing portfolio investments in the pharmaceuticals and biotechnology areas in Europe.

Jeanne has over 25 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development. She spent 11 years in Licensing and Acquisition, most recently as Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, having joined the Johnson & Johnson Family of Companies in 2005 from the Business Development group at GSK. In 2009, Jeanne became VP Alliance Management and Board Director at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan on immunotherapies targeting beta amyloid for Alzheimer’s disease.

Jeanne received her medical degree from University College Dublin. She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA). She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). She has served as the sole pharmaceutical industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.

Robert Tansley

Non-Executive Director

Robert joined Cambridge Innovation Capital as Investment Director in January 2014.

After seven years working in hospital medicine, Robert joined the pharma industry in 1996 working in development and regulatory roles at Sanofi, the MHRA and Roche where he led the clinical team for the regulatory approval of Valcyte^®. Ten years ago, Robert joined the Cambridge based company Arakis and worked as Medical Director until its £106m sale to Sosei Inc. Since that acquisition, Robert has been involved in a number of start-up companies including founding the malaria-focused company Treague, being founding CEO of the University of Copenhagen spin-out Avilex Pharma and being part of the founding management team of KalVista which is developing the first plasma kallikrein inhibitor for diabetic macular edema in collaboration with its scientific co-founders from Harvard Medical School.

Robert qualified in medicine from University College London, he is a member of the Royal College of Obstetricians & Gynaecologists and the Faculty of Pharmaceutical Medicine and has an MBA from London Business School and an M.Phil in Biostatistics from the University of Cambridge.

Jeff Buchalter

Non-Executive Chairman

Jeff joined Inivata after a long and successful career in the bio/pharmaceutical industry most recently as Chief Executive Officer of Archimedes Pharma Ltd.

His experience combines strong corporate leadership allied to an extensive background in medical/clinical research with multinational organisations. He brings extensive commercial and drug development experience in oncology and other therapeutic areas.

Jeff has been recognised for his work, receiving the Joseph F. Buckley Memorial Award from the American Cancer Society for commitment to cancer control and involvement in the oncology pharmaceutical field. He has also been a Collaborating Partner in the President’s National Dialogue on Cancer and acted as Chairman of the Board of Directors to the National Childhood Cancer Foundation in the United States.

Jeff received a Bachelor of Science Degree in Finance from Seton Hall University and a Master of Business Administration in Marketing from Temple University.

Jamie Platt PhD

Chief Operations Officer

Jamie leads the global clinical laboratory operations at Inivata. She was engaged as a consultant in March 2017 and joined the team on a full-time basis in Sept 2017. She has extensive expertise in sequencing and molecular systematics, including population genetics.

During her 15 years in clinical diagnostics, Jamie has developed and validated numerous high complexity sequencing assays in the clinical areas of Oncology, Infectious Disease and Molecular Genetics and has introduced custom, industrial-grade automation to high complexity, sequencing assays.

She has spent more than 10 years overseeing development and validation of Next Generation Sequencing Assays for both clinical diagnostics and clinical trials and has special interest in applying advanced sequencing technologies (NGS) to improve personalized healthcare. Jamie received her PhD in Molecular and Cellular Biology from Oregon State University and completed postdoctoral training in population genetics at the University of California, Berkeley.

Patrice Love

Director of People and Organisation Development

Patrice has led HR activities since the early formation of the company in 2014. She has experience in early stage start-ups and pre-IPO companies, particularly in the life science and technology sectors, both in Europe and USA. Patrice’s career started in BT and in the latter years, with BT Brightstar, BT’s first corporate incubator as Head of Operations.

She was also a Director at British manufacturer, Timberwolf and before joining Inivata, she owned her own consultancy business, supporting start-ups with a range of services including Operations, HR, Marketing and Finance. During her consultancy, she moved to New York for a year where she set up a US business for a UK technology company. Patrice is a Board Member of the Suffolk Chamber of Commerce, Suffolk Business Women, and an Ambassador for Suffolk Inward Investment and until recently, a Trust Governor at Suffolk One college.

Charlie Kesinger

Chief Information Officer

Charlie Joined Inivata as Chief Information Officer December 2018. Prior to joining Inivata he led international technology operations for D-Wise, a consulting firm focusing on healthcare and life sciences. Before that he worked for Medsolutions, a billion-dollar healthcare-based decision support organization where he headed IT Excellence & Reliability.

Charlie has also served as a Chief Operations Officer at Emergisoft, a healthcare-based electronic medical records management company where he delivered systems to enterprise clients and successfully launched electronic medical records for maritime. Charlie is currently concluding his Ph.D. in Organizational Leadership. He attended Northwestern University to obtain a Master of Science (Medical Informatics). His undergrad is in Business Administration.

Edward S Kim MD

Chairman SAB

Edward S. Kim, MD is Chair of Solid Tumor Oncology and Investigational Therapeutics, Medical Director of the Clinical Trials Office, and the Donald S. KimDistinguished Chair for Cancer Research at the Levine Cancer Institute, Carolinas HealthCare System in Charlotte, NC.

Dr. Kim was previously at UT MD Anderson Cancer Center in Houston, Texas where he was a tenured Associate Professor of Medicine, Chief of the Section of Head and Neck Medical Oncology and Director of Clinical Research Operations in the Department of Thoracic/Head and Neck Medical Oncology.

Dr Kim received his Bachelor of Science and medical degrees from the Honors Program in Medical Education (HPME) at Northwestern University, his residency at Baylor College of Medicine, and his fellowship in medical oncology at UT MD Anderson Cancer Center.

Dr Kim specializes in cancer biomarkers and novel targeted agents in the treatment and prevention settings and has expertise in lung, head and neck cancers. He chaired the Department of Defense Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) personalized medicine program in lung cancer. He currently oversees the solid tumor faculty and research development at Levine Cancer Institute.

Dr Kim is the author or coauthor of more than 100 published articles, book chapters, reviews in journals such as Lancet, Lancet Oncology, Journal of Clinical Oncology, Cancer Discovery, Clinical Cancer Research Cancer, and Cancer Prevention Research, involving cancer therapeutics and prevention with chemotherapy and novel targeted agents, with particular emphases on lung cancer and head and neck cancer.

Geoffrey R Oxnard MD

Dr. Oxnard is a thoracic oncologist at the Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School. He graduated with honors from the University of Chicago School of Medicine, received his medical training at Massachusetts General Hospital, and performed oncology fellowship at Memorial Sloan-Kettering Cancer Center.

He is a clinic-based translational investigator whose research includes studies of targeted therapies for genotype-defined NSCLC populations, familial lung cancer due to germline EGFR mutations, and noninvasive plasma genotyping technologies. He was previously awarded with a Young Investigator Award and Career Development Award from the Conquer Cancer Foundation of ASCO, a Career Development Award from the US Department of Defense, and has recently been named a Damon Runyon Clinical Investigator. He has given oral presentations on his research at the Annual Meeting of the American Society of Clinical Oncology, the Annual Meeting of the Radiological Society of North American, and the World Conference on Lung Cancer.

Lee S Schwartzberg MD, FACP

Lee S. Schwartzberg, MD, is the Executive Director of the West Cancer Center, a multispecialty oncology practice comprising over 40 medical oncologists, gynecologic oncologists, radiation oncologists, surgical oncologists, palliative care experts, radiologists and other oncology related physicians located in Memphis, Tennessee. Dr. Schwartzberg also serves as Professor of Medicine and Division Chief of Hematology/Oncology at The University of Tennessee Health Science Center. He also is President/CMO for Vector Oncology, an oncology specific SMO/CRO.

Dr Schwartzberg received his medical degree from New York Medical College. After completing his internal medicine residency at Cornell University/North Shore University Hospital, Dr Schwartzberg continued his training with a medical oncology and hematology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC). During his tenure at MSKCC, Dr Schwartzberg served as Chief Medical Resident and was a founding member of the institutional ethics committee.

Dr Schwartzberg’s specializes in the treatment of breast cancer, with a specific research focus on new therapeutic approaches, targeted therapy, and supportive care. Dr. Schwartzberg has published more than 150 peer reviewed articles in peer-reviewed journals, including Journal of Clinical Oncology, Lancet Oncology, and Annals of Oncology.

Dr Schwartzberg was the founding editor-in-chief of the journal Community Oncology and currently serves as the editor-in-chief of the Practice Update Oncology website. He serves on the editorial board of both the Journal of Supportive Oncology and The ASCO Post, in addition to serving as a reviewer for many prominent medical journals, including The New England Journal of Medicine and Journal of Clinical Oncology.

Dr Schwartzberg serves on the NCCN Board of Directors and the NCCN Guidelines Steering Committee. He also is a member of the NCCN Breast Cancer Panel, the NCCN Myeloid Growth Factors Panel, and the NCCN Antiemesis Panel. Additionally, Dr. Schwartzberg is a member of the NCCN Oncology Research Program Investigator Steering Committee.

Dr Jean-Charles Soria

Dr Jean-Charles Soria is currently Senior Vice President and Head of the Oncology Innovative Medicines unit (iMED) at MedImmune, where he leads cross-functional teams responsible for the strategy, growth, and advancement of the early oncology biologics portfolio, which includes oncology research, translational medicine, and early oncology development.

Previously, he was a Professor of Medicine and Medical Oncology at South-Paris University from 2006-2017.

As a medical oncologist and scientist, he made substantial research contributions toward potential therapeutic treatments for cancer throughout his career, especially in precision medicine and immuno-oncology. His main research interests have been: early clinical development, phase I trials across solid tumors, pharmacodynamic biomarkers, lung cancer and personalized medicine. He has contributed to over 550 peer-reviewed publications, including publications as first or last author in the New England Journal of Medicine, Lancet Oncology, JCO, Annals of Oncology.

His education includes being trained as a medical oncologist and obtaining the Silver medal from Paris Medical School in 1997. He also gained a PhD degree summa cum laude in the fundamental basis of oncogenesis in 2001, and completed his training with a two-year post-doctoral fellowship in the Department of Thoracic Head and Neck Medical Oncology at MD Anderson Cancer Center, Houston, USA, where he held an Adjunct Professorship in 2012.

Sandra Swain MD, FACP, FASCO

Sandra M. Swain, MD, FACP, FASCO is a Professor of Medicine and the Associate Dean for Research Development at the Georgetown University Medical Center (GUMC) in Washington, DC. She is also an Adjunct Professor of Medicine at the Uniformed Services University of the Health Sciences. In her primary role as Associate Dean for Research Development, Swain works closely with industry and community partners to improve patients’ access to cutting-edge treatments and technologies by expanding medical research opportunities both at GUMC and across the MedStar Health system.

Swain graduated with a Bachelor of Arts (B.A.) in Chemistry from the University of North Carolina in
1975 and earned her Doctor of Medicine (M.D.) from the University of Florida in Gainesville in 1980. She completed a residency in Internal Medicine at Vanderbilt University in 1983 followed by a fellowship in Medical Oncology at the National Institutes of Health, National Cancer Institute in 1986. She served at the National Institutes of Health as the Deputy Branch Chief for the Medicine Branch of the Center for Cancer Research at the NCI as a tenured Principal Investigator. Next at the NIH, she became the Head of the Breast Cancer Section, and Chief of the Cancer Therapeutics Branch. From 2007-2016 she served as the Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center in Washington, DC.

Swain’s research interests include translational research and clinical trials focused on metastatic and inflammatory breast cancer, adjuvant therapy for breast cancer, cardiotoxicity, and health care disparities. Her research has received funding from the National Institutes of Health, Susan G. Komen Foundation, Breast Cancer Research Foundation, and the Avon Foundation. She has published over 270 articles and is internationally recognized as a leader in the field breast cancer research and treatment. Moreover, Swain has received numerous awards and recognitions for her work, including the Susan G. Komen Award of Distinction for Community Service in 2012. She is also a recipient of the National Institutes of Health Merit Award, as well as a two-time recipient of the National Cancer Institute Mentor of Merit Award. In 2012, she received the Claude Jacquillat Award for Clinical Cancer Research and in 2016, the 3rd Aleksandr Savchuk Prize, Aleksandr Savchuk Foundation. The Washington Business Journal honored Swain with its prestigious Women Who Mean Business award in 2016.

Swain was a member of the American Society of Clinical Oncology (ASCO) Board of directors and served as President from 2013-14. She is currently a member and treasurer of the Conquer Cancer Foundation Board of Directors of ASCO. She sits on the Executive Committee of the Lombardi Comprehensive Cancer Center at GUMC. She has actively contributed to the National Surgical Adjuvant Breast and Bowel Project for over 30 years, as Vice-Chair of the Breast Committee and a Principal Investigator of adjuvant trials for breast cancer. She currently is an active member of the NRG Breast Committee. She is a Fellow of the American College of Physicians and ASCO. She is a member of both the American Association of Cancer Research and the American Medical Association.

Inivata Boosts Executive Team with appointment of Clive Morris as Chief Medical Officer

“Analysis of ctDNA has huge potential to help oncologists manage their patients more effectively and I look forward to helping Inivata play a major part in this transformation. I’m really pleased to be joining the team at such an exciting time for the company and the ctDNA field generally.”

About Inivata

Media Contacts

Our Technology

Our Solutions

Latest News